Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (Nasdaq: AKTX) announced Australian patent acceptance (Application No. 2024201765) covering composition-of-matter claims for proprietary 2nd-generation Thailanstatin analog PH1 payloads designed for ADC therapeutics.
The approval expands global IP alongside issued patents in the US, China, India, Japan, Israel, and Mexico and supports advancement of AKTX-101 and the ADC pipeline; AKTX-101 is in IND-enabling studies with a Phase 1 first-in-human trial targeted for late 2026/early 2027. The company cites a TROP2 ADC market opportunity of about $12B by 2033.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. The abstract describes AKTX-101 combination synergy with a K-Ras inhibitor in KRAS-mutated pancreatic cancers. Publication is scheduled for May 21, 2026 at 5:00 PM ET. Akari said this is its first ASCO acceptance and supports advancement of AKTX-101 into Phase 1 by late 2026/early 2027.
Akari Therapeutics (Nasdaq: AKTX) reported positive preclinical results for AKTX-101, a TROP2-targeting ADC using a novel RNA splicing modulator payload (PH1). AKTX-101 showed sub-nanomolar potency in bladder and selected lung and breast cancer models and greater cytotoxicity versus TROP2 ADCs with Topoisomerase I inhibitor payloads.
The company plans an IND submission in Q4 2026 and initiation of a Phase 1 study in Q1 2027; data were presented at AACR 2026.
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala discussed the company’s strategic partnership with WuXi XDC, calling it a milestone that validates Akari’s PH1 spliceosome‑modulating payload platform.
The interview said the collaboration goes beyond a typical CDMO role, is expected to reduce execution risk and accelerate an IND filing for AKTX-101 to late 2026, and positions Akari within the evolving ADC market.
Akari Therapeutics (Nasdaq: AKTX) announced a strategic partnership with WuXi XDC to accelerate development of its novel PH1 ADC payload and advance lead program AKTX-101. Akari aims to accelerate an IND filing by late 2026 and begin a Phase 1 trial in late 2026 or early 2027, subject to regulatory clearance.
The collaboration targets RNA splicing modulation as a differentiated ADC mechanism after preclinical anti-tumor regression and complete remissions versus comparators.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for a poster at the American Association for Cancer Research Annual Meeting 2026, April 17–22, 2026.
The poster, "Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breast," will be presented April 20, 2026, 2:00–5:00 PM PT in Poster Section 19 and posted online after 5:00 PM PT.
Akari Therapeutics (Nasdaq: AKTX) will change its American Depositary Share ratio from 1 ADS = 2,000 ordinary shares to 1 ADS = 80,000 ordinary shares, effective March 31, 2026. ADS holders must exchange every forty ADSs for one new ADS.
Deutsche Bank will arrange the exchange, no fractional new ADSs will be issued, and fractional entitlements will be aggregated, sold, and distributed in cash (net of fees). Akari said the change aims to help maintain Nasdaq minimum bid price compliance and cautioned it cannot assure post-change ADS price performance.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner from Abizer Gaslightwala reviewing his first year and strategic progress toward clinical development.
Highlights include advancement of the PH1 ADC payload platform, lead program AKTX-101 (Trop2-targeted) with a non-cleavable linker, initiation of IND-enabling activities with WuXi XDC, a target IND/CTA filing goal in late 2026 or early 2027, introduction of AKTX-102 targeting CEACAM5, multiple provisional patent filings, and formation of a scientific advisory group.
Akari Therapeutics (Nasdaq: AKTX) appointed Prafulla Gokhale, Ph.D., to its Scientific Advisory Board on Feb 26, 2026. Dr. Gokhale brings 20 years in preclinical oncology, RNA biology and translational therapeutics to support advancement of AKTX-101 and the company’s PH1 spliceosome-modulating payload toward first-in-human studies.
His experience directing translational programs and integrating genomics, patient-derived models and imaging is expected to refine AKTX-101's clinical strategy and translational experiments.
Akari Therapeutics (Nasdaq: AKTX) appointed Olga Anczukow, Ph.D., to its Scientific Advisory Board on February 23, 2026. Dr. Anczukow is an internationally recognized RNA biology and cancer researcher with roles at The Jackson Laboratory and University of Connecticut.
The appointment reinforces Akari's focus on advancing its PH1 ADC payload that targets RNA splicing in cancer cells and aims to strengthen translational research and scientific strategy.